Kornimate/medical-research-clean huggingface dataset:
sarcopenia in copd patients: a french study

Conditions: COPD

Summary: the prevalence of sarcopenia is high in many organ pathologies such as copd, but remains little studied in acute respiratory failure. sarcopenia is a health problem representative of frailty, loss of autonomy and decreased muscle strength. the frequency and evolution of sarcopenia is unknown in patients having chronic bronchic obstruction with exacerbation.

* investigator consecutively included patients with known persistent airflow obstruction, hospitalized in pneumology department at the chu gabriel montpied in clermont-ferrand. * investigator offered to participate to an observational study involving nutritional evaluation (recommended by national and international authorities) complementary to their usual respiratory care, and a 6 months' follow-up consultation: examination and surveys, mid-arm muscle circumference, body composition, spirometry. * this enables to assess sarcopenia as a low mid-arm muscle area, by measuring the mid-arm muscle circumference of the dominant side and the triceps skinfold thickness. * the primary endpoint is to determine the prevalence of sarcopenia, via the brachial muscular circumference, of chronic obstructive patients hospitalized in pneumology department. * the data entry (clinical, biological and radiological) is carried out on site, during the initial consultation and follow-up, directly on the computerized patient file. these data will then be retrieved and entered in an excel spreadsheet, anonymously (anonymous identification number, gender and age). * management of censored data (lost to follow-up, cessation or withdrawal of study): each patient has a "computerized patient record" with phone numbers, checked during the first consultation and updated if necessary. the patient is called back one month before the follow-up consultation to confirm the appointment. if it is impossible to come, the patient will be offered another appointment, within one month of his initial appointment. * lost participants will not be excluded from statistical analyses. * the expected number of subjects is 50. * oral and written consent is asked at the beginning of the consultation proposing participation in the study and follow-up at 6 months.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * a history of persistent airflow obstruction (a post-bronchodilator fev1/fvc \< 0.7 of the predicted value after 400 ug of inhaled salbutamol) compatible with respiratory function tests (according to the gold definition) * informed consent to examination of nutritional status exclusion criteria: * bronchopulmonary cancer being treated * disabling rheumatic disease * recent stroke or surgery (\< 3 months) * missing data on essential variables (bmi, mid-arm muscle circumference)

Keywords: copd sarcopenia prevalence mortality malnutrition nutritional assessment body composition pulmonary cachexia
repara study: registry of patients with bioresorbable device in daily clinical practice

Conditions: Coronary Artery Lesions With Implantation of Coronary Device

Summary: a multicentre, observational, prospective device registry, with no control group, designed to evaluate the efficacy and safety of the bioresorbable coronary device, used according to the indications of use, in daily clinical practice in a consecutive number of patients undergoing pci in de novo coronary artery lesions. a total of 1,500 patients are planned to be included in the registry.

the patients will be included consecutively at each site for one year. they will be individuals from both sexes, requiring endovascular intervention and meeting the authorised criteria for the indications of use of the device to be used and where dual anti-platelet therapy (dapt) with aspirin and thienopyridines is considered. study objectives to evaluate the mace rate after implantation of the bioresorbable coronary device in patients with de novo coronary artery lesions, where a follow-up of 12 months will be performed. primary objective: mace rate at 12 months of follow-up: cardiac death myocardial infarction tlr driven by ischaemia of the lesion treated or of the region of 5 mm proximally or distally to the site of implantation of the device (id-tlr). secondary objectives: * angina * death due to any cause. * myocardial infarction of any type (mi: qmi, nqmi, tv, ntv) * all tlr driven or not by ischaemia * all tvr driven or not by ischaemia. * all coronary revascularisations performed (pci vs cabg) * device thrombosis (acute, sub-acute, late) and evidence (definitive, probable, possible). * immediate success of the device. * immediate success of the procedure. * rate of patients with dapt at \< 1 month, 1-3 months, 3-6 months, and 6-12 months and relationship with the occurrence of events * composite endpoints: cardiac death, tv-mi and id-tlr: (target lesion failure (tlf)) cardiac death, any myocardial infarction (mi) and id-tvr: (target vessel failure (tvf)) * rate of overlapping devices: characteristics and relationship with occurrence of events * collection of imaging data of the cases where, according to the judgement of the investigator, intravascular imaging tests have been performed (ivus, oct).

Eligibility criteria:
inclusion criteria: * patient must be at least 18 years of age at the time of signing the informed consent form * patient is to be treated for de novo coronary lesions in a native coronary artery and amenable to receive a bioresorbable device * the length of the treated lesion should be inferior to the nominal length of the device (12 mm, 18 mm, 28 mm) with a reference vessel diameter \> 2 mm y \< 3,8 mm. * the patient will not have any relative contraindication for double antiplatelet therapy, with aspirin indefinitely and with a thienopyridine for at least 6 months exclusion criteria: * cardiogenic shock * left main disease * aortocoronary graft * intrastent restenosis * potentially child-bearing women with no contraceptive methods * pregnant or breast-feeding women

Keywords: coronary artery disease; angioplasty; bioresorbable device
a study to test lung function after radiation therapy

Conditions: Lung Neoplasms; Neoplasm Metastasis

Summary: it is known that radiation damages lung tissue. new human studies at university of iowa show that the radiation damage is not as expected. the purpose of this study is to document lung function using four-dimensional computed tomography (ct) and quantify changes three months after radiation therapy for malignant lung disease.


Eligibility criteria:
inclusion criteria: * histological diagnosis of small cell or non-small cell lung cancer or metastatic tumor to the lung being scheduled for localized radiation therapy (including radiosurgery) * no prior or future planned surgery for the treatment of the lung cancer. * age ≥ 18 years * karnofsky 60% * not pregnant. * ability to understand and the willingness to sign a written informed consent document * ability and willingness to participate in breathing training and compliance wiht breathing apparatus so that radiation doses are optimally linked to 4d-ct images * ability to tolerate ct contrast exclusion criteria: * no prior thoracic radiotherapy will be permitted * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * pregnant women * severe copd that requires chronic prednisone or multiple inhalers * underlying collagen vascular disease or intrinsic lung disease that could complicate expected sequelae of radiation (idiopathic pulmonary fibrosis, wegener's granulomatosis) * oxygen dependence at baseline * recent lung surgery or abdominal surgery (within 3 weeks) that would compromise respiratory pattern.

Keywords: radiation tomography, spiral computed four-dimensional computed tomography respiratory function tests
attention capacity and before-school physical activity intervention program

Conditions: Physical Activity; Behavior; Child Behavior; Attention Deficit Hyperactivity Disorder

Summary: despite the evidence and the potential of physical activity related to cognition and academic performance in children, the effects of a before-school physical activity program on these parameters remains unknown.

despite public health concerns and the extensively documented health benefits of physical activity, a large proportion of chilean children do not meet the physical activity recommendations (aguilar-farias et al., 2018). since most children spend a majority of their waking hours at school, this environment is appropriate for the implementation of preventive interventions, particularly those that include activities promoting physical activity (naylor \& mckay, 2009). with the absence of opportunities for physical activity during the school day, before-school programs have become a popular option to help children increasing their physical activity levels (stylianou, van der mars, et al., 2016). although several recent studies support a positive effect of before school-based physical activity on health (westcott, puhala, colligan, loud, \& cobbett, 2015), less literature has evaluate the cognitive outcomes (stylianou, kulinna, et al., 2016) such as attention capacity.

Eligibility criteria:
inclusion criteria: * all students in fourth grade (aged 8-10 years) * children's parents/caregivers will give their written consent to the children's participation. * collaboration in the family to respond to questionnaires exclusion criteria: * children with some physical pathology or medical contraindication to perform physical exercise * diagnosed with learning disabilities or mental disorders

Keywords: exercise prevention attention capacity
comparison between latanoprost , travoprost and tafluprost in reducing iop fluctuation in poag patients

Conditions: Primary Open Angle Glaucoma

Summary: elevated iop is a key risk factor for the progression of glaucoma. iop is subjected to diurnal fluctuation in healthy individuals and higher fluctuation in poag . so, once-daily antiglaucoma drugs must have consistent efficacy throughout the day. prostaglandin analogues (pgas) have become the first-line drops for medical treatment of glaucoma worldwide. in our study, we compare between the efficacy and tolerability of latanoprost 0.005%, travoprost 0.004% and tafluprost 0.0015% on diurnal iop fluctuation in patients having poag, iop fluctuation was assessed before treatment , then 2 weeks and 6 weeks after. a comparable and significant reduction in iop fluctuation occurred in the 3 groups. side effects were mild and tolerable.


Eligibility criteria:
inclusion criteria: * both genders aged 18 years or more. * newly diagnosed poag cases having : iop more than 21 mmhg open angle on gonioscopy showing both structural and functional damage (confirmed with oct and visual field) exclusion criteria: * angle closure glaucoma. * secondary glaucomas. * advanced glaucoma likely to be uncontrolled on monotherapy or needing a low target iop. * history of ocular trauma, laser or intraocular surgery. * any other ocular disorder including uveitis and cystoid macular edema. * known history of allergy or sensitivity to any components of the study medications.

Keywords: prostaglandin analogues
re-orchestration of interregional oscillatory activity to promote visual recovery

Conditions: Visual Impairment; Stroke; Parkinson Disease

Summary: this project assesses the effect of bifocal cross-frequency transcranial alternating current stimulation (tacs) combined with visual training to improve visual recovery and orchestrated oscillatory activity in stroke patients suffering from visual field defects.


Eligibility criteria:
inclusion criteria: 1. the patient can consent for themselves; 2. age 18+ years old; 3. at least 7 days since diagnosis "stroke". 4. patients should demonstrate a clear deficit in either simple or complex visual perception in portions of their visual field exclusion criteria: 1. diminished capacity to consent; 2. pregnancy 3. known or suspected non-compliance, drug or alcohol abuse 4. inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant, 5. non-compliance to the instructions of the experimenter or an inappropriate behavior hindering the normal progress of the experiment. 6. previous enrolment into the current study 7. exclusion criteria of mri, tacs, tms 8. use of psychoactive medication

Keywords: stroke visual field oscillations tacs parkinson's disease
internet-delivered cognitive behavior therapy for atrial fibrillation

Conditions: Atrial Fibrillation; Arrhythmia

Summary: the aim is to evaluate if internet- delivered cognitive behavior therapy (cbt), based on exposure principles and behavioral activation, improves qol and symptom burden in patients with symptomatic atrial fibrillation (af) compared to treatment as usual. the study will include 120 patients with symptomatic af despite optimal medical treatment in accordance with current guidelines.

atrial fibrillation (af) is the most common cardiac arrhythmia (irregular heartbeat) affecting 3% of the population. af is associated with poor quality of life (qol) and large costs for society. in a considerable proportion of patients, af symptoms (e.g., palpitations, fatigue, and chest pain) are not alleviated by current medical or interventional treatments. psychological factors can worsen af symptoms, and anxiety and depression are common among af patients. symptom preoccupation and avoidance of social and physical activities are likely to play important roles in the development of anxiety, depression, disability and healthcare utilization. the aim is to evaluate if cbt, based on behavioral activation and exposure principles, improves wellbeing and qol in symptomatic af patients more than a wait list offered treatment as usual. method: a randomized controlled trial. participants are randomized to internet-delivered cbt for 10 weeks (n=60) or to treatment as usual (n=60). the internet-delivered cbt-program will last for 10 weeks and include weekly therapist support, consisting of online messages and telephone calls. patients on the treatment as usual wait list will be provided standardized written information about basic self-management in af. the treatment as usual wait list will be crossed over to treatment 3 months after the treatment group has completed treatment.

Eligibility criteria:
inclusion criteria: * inclusion criteria: a) paroxysmal af ≥ once per month that causes moderate to severe symptoms and leads to significant distress or interferes with daily life (i.e. ehra class ≥ iib) ; b) age 18-75 years; c) on optimal medical treatment; d). able to read and write in swedish. exclusion criteria: * (e) heart failure with severe systolic dysfunction (ejection fraction ≤ 35%); (f) significant valvular disease; (g) planned ablation for af or ablation within 3 months before assessment; (h) other severe medical illness; (i) any medical restriction to physical exercise; (j) severe psychiatric disorder, severe depression, or risk of suicide; (k) alcohol dependency.
safety, tolerability, and pharmacokinetics of cat-192 (human anti-tgf-beta1 monoclonal antibody) in patients with early stage diffuse systemic sclerosis

Conditions: Systemic Sclerosis; Scleroderma

Summary: systemic sclerosis (also known as scleroderma) is a chronic, autoimmune disease of the connective tissue generally classified as one of the rheumatic diseases. systemic sclerosis causes fibrosis (scar tissue) to be formed in the skin and internal organs. the fibrosis eventually causes the involved skin to harden, limiting mobility, and can also damage other organs. excess transforming growth factor beta-1 (tgf-beta1) activity may result in the abnormal fibrosis characteristic of systemic sclerosis. an antibody against tgf-beta1 may modify pathologic processes characterized by inappropriate fibrosis. genzyme corporation is currently investigating a human monoclonal antibody (cat-192) that neutralizes active tgf-beta1. this study is being conducted in the u.s. and europe to evaluate the safety, tolerability, and pharmacokinetics of repeated treatments with cat-192 in patients with early stage diffuse systemic sclerosis.


Eligibility criteria:
inclusion criteria: * diagnosis of diffuse systemic sclerosis * duration of disease 18 months or less * modified rodnan skin score in a range as identified by the study protocol * evidence of worsening disease activity * ability to attend follow-up assessments for a minimum of 9 months * agree to delay elective surgery during the trial and up to 9 months after final infusion * agree to delay reproduction during the trial and up to 9 months after final infusion exclusion criteria: * women who are pregnant or lactating * clinical evidence of other definable connective tissue or autoimmune disease * severe kidney, heart, lung, or gastrointestinal disease * treatment with protocol-specified immunosuppressants within 4 weeks of starting the clinical study * treatment with systemic corticosteroids in a dose greater than 10 mg/day of prednisone or equivalent (inhaled steroids at standard doses are allowed) * current treatment by photopheresis
application value of whole-procedure optimization for catheter ablation of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the success rate of single-procedure atrial arrhythmia-free survival particularly ranged from 40% to 66% in persistent af ablation. however, the surgical cox maze iii procedure has been established to be an effective curative strategy for af with an af-free survival rate of more than 95%. the main reason is the difficulty of creating continuous, transmural, and durable lesions by catheter ablation, especially when the procedure is performed on some complex anatomical structures in which epicardial muscular bundles may serve as components of the reentrant circuits. the durability of the conduction block is a crucial factor for long-term effective af ablation since previous studies reported that the reconnected pulmonary veins contributed to the atrial tachycardia recurrence after persistent af ablation. in addition, it is possible that the inadequate lesions accidentally produce new arrhythmogenic substrates. therefore, new and better techniques are always chosen to minimize the reconnection of pulmonary vein isolation (pvi) and additional ablation. for paroxysmal af, the ablation strategy of pvi plus superior vena cava isolation is chosen while pvi, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus (cti) for persistent af. any symptomatic or asymptomatic atrial arrhythmia lasting more than 30 seconds was regarded as an af recurrence after a 3-month blanking period. the primary outcome was defined as 12-month atrial arrhythmia-free survival. the secondary outcomes include the block rate of pvi, superior vena cava isolation, and all linear ablations.


Eligibility criteria:
inclusion criteria: * radiofrequency catheter ablation for the first time * af rhythm recorded by ecg exclusion criteria: * thrombosis in left atrium * left ventricular ejection fraction of \< 35% * abnormal thyroid function * previous history of af radiofrequency ablation and cabg * left atrium diameter of \> 65 mm or the volume of \> 200 ml

Keywords: atrial fibrillation catheter ablation optimized strategies and workflows
self-management of sleep among older adults

Conditions: Sleep Disturbance

Summary: the purpose of this study is to test the feasibility of older persons use of a personal sleep monitoring device(psmd)to improve self-management of sleep. disrupted sleep occurs in up to 50% of persons over the age of 65 with chronic health conditions. impaired sleep negatively influences subjective and objective health outcomes.to improve their sleep, older adults with chronic health conditions could benefit from objective information, available through personal health monitoring devices, about their current and changing sleep patterns. based on this information, sleep self-management interventions can be individualized and shared, and associations between sleep and health changes may be better managed.


Eligibility criteria:
inclusion criteria: * 65 years or older * self-report difficulty sleeping * willingness to wear the psmd for four weeks * cognitive abilities (mini cog of 5 or above). exclusion criteria: * under the age of 65 * presence of known sleep disorders * severe cognitive or neurosensory impairment

Keywords: older people sleep disturbance self-monitoring self-management social support wrist-worn actigraphy
study of conscious behavior under low-frequency deep brain stimulation in chronic and severe post-coma disorders of consciousness

Conditions: Chronic and Severe Post-coma Disorders of Consciousness (Permanent Vegetative State, Minimally Conscious State)

Summary: chronic post-coma consciousness impairment is a severe handicap. preliminary studies suggest that deep brain stimulation of the thalamic-tegmental reticular system could improve consciousness disorders, and facilitate the emergence of conscious behavior. the aim of this protocol is to study the effects of deep brain stimulation on conscious behavior, using a patient-based anatomic mapping for stereotactic surgery, and the coma recovery scale-revised (crs-r) as clinical assessment criterion.

total length of inclusion for a patient: 10 months (2 months before electrodes implantation, 8 months after).

Eligibility criteria:
inclusion criteria: * patients stably in vegetative state or minimally conscious state, since at least 6 months after cerebrovascular accident and 1 year after traumatic brain injury. exclusion criteria: * cerebral death, locked-in syndrome, blindness, deafness

Keywords: deep brain stimulation (dbs) post-coma consciousness vegetative state minimally conscious state
chronic rhinosinusitis in a danish population: evaluation of causes of disease, progress and treatment

Conditions: Chronic Rhinosinusitis

Summary: introduction: chronic rhinosinusitis (crs) is defined as inflammation of the nose and the paranasal sinuses. it is a very common disorder increasing in both incidence and prevalence with significant impact on quality of life and substantial health care costs. in this study we evaluate the prevalence of crs in denmark and there is a need for consensus about diagnosing this disease. different questionnaires and different tests used for examination are evaluated together with the patients compliance and days lost through illness. methods: as part of ga2len (global asthma and allergy european network) a questionnaire on crs was posted to 5000 residents on funen. from the completed and returned questionnaires self reported crs was evaluated. respondents were invited for clinical examination including spirometry, skin prick test, bloodsample and an ent examination including nasal endoscopy, acoustic rhinometry, peak nasal inspiratory flow and smell test. questionnaire on quality of life (eq-5d) and symptom severity (snot-22) was completed. medical diagnosed crs was diagnosed according to the definition on crs stated by epos (european position paper on rhinosinusitis and nasal polyps 2007). crs is defined as inflammation in the nose and paranasal sinus and should be characterized by two or more symptoms one of which should be either nasal blockage/obstruction/congestion or nasal discharge, +/- facial pain/pressure, +/- reduction or loss of smell. endoscopic signs should be present and symptoms must have been present \> 12 weeks. patients diagnosed with crs were invited for a 1 year and 2 year follow up where examination and questionnaires were repeated and treatment compliance and days lost through illness were evaluated.


Eligibility criteria:
inclusion criteria: * residents on funen aged 18-75 years exclusion criteria:

Keywords: chronic rhinosinusitis, snot 22, quality of life